USA2SUMMIT.ORG - Key Persons

Job Titles:

• Director of Cognitive Disorders, Advocate Medical Group ( Ill. ) Neurosciences Medical Research Director and Senior Medical Director, Advocate Memory Center, Advocate Health Care

Dr. Darren Gitelman studied medicine at Washington University in St. Louis, Mo. He completed an internal medicine residency at the Columbia-Presbyterian Medical Center in New York, N.Y., followed by a fellowship in brain imaging at the New York State Psychiatric Institute. He was then a neurology resident and chief resident at the Massachusetts General Hospital in Boston, Mass. Dr. Gitelman joined the Neurology faculty at Northwestern University, Chicago, Ill., in 1994. In 2014 he joined Advocate Health as the senior medical director of the Advocate Memory Center. He is a Clinical Professor of Medicine at the Rosalind Franklin University of Medicine and Science, North Chicago, Ill., and Adjunct Associate Professor of Neurology at the Feinberg School of Medicine, Northwestern University. His current research is focused on clinical drug trials and enhancing cognitive testing in older adults. Dr. Gitelman has engaged in consulting/advisory activities with AbbVie, Biogen, Eisai Inc., Genentech/Roche, Lilly, and Novo Nordisk. He has engaged in clinical trial investigator activities with Biogen, Cassava, Eisai Inc., and Lilly.

Job Titles:

• Is Director

Dr. David B. Reuben is Director, Multicampus Program in Geriatrics Medicine and Gerontology, and Chief, Division of Geriatrics, at the University of California, Los Angeles (UCLA) Center for Health Sciences. He is the Archstone Foundation Chair and Professor at the David Geffen School of Medicine at UCLA and Director of the UCLA Alzheimer's and Dementia Care Program. Dr. Reuben is a past President of the American Geriatrics Society and the Association of Directors of Geriatric Academic Programs. He served for eight years on the American Board of Internal Medicine's Board of Directors, including as Chair from 2010 to 2011. From 2016 to 2022, Dr. Reuben served as a trustee of the American Board of Internal Medicine Foundation. In 2000, Dr. Reuben received the Dennis H. Jahnigen Memorial Award for outstanding contributions to education in the field of geriatrics and, in 2008, he received the Joseph T. Freeman Award from the Gerontological Society of America. He was part of the team that received the 2008 John M. Eisenberg Patient Safety and Quality Award for Research - Joint Commission and National Quality Forum, for Assessing Care of the Vulnerable Elderly. In 2012, he received the Henderson Award from the American Geriatrics Society. In 2012, Dr. Reuben received one of the first CMMI Innovations Challenge awards to develop a model program to provide comprehensive, coordinated care for patients with Alzheimer's disease and other dementias. In 2014, he was one of three principal investigators to be awarded a multicenter clinical trial (STRIDE) by the Patient-Centered Outcomes Research Institute (PCORI) and the National Institute on Aging (NIA) to reduce serious falls related injuries; it is the largest grant that PCORI has awarded. In 2018, he was awarded a multi-site PCORI- and NIA-funded pragmatic trial (D-CARE) to compare the effectiveness of health system-based dementia care versus community-based dementia care versus usual care. Dr. Reuben was co-chair of the 2020 National Research Summit in Care, Services, and Supports for Persons with Dementia and their Caregivers. He is a member of the National Advisory Council on Aging for the National Institute on Aging. Dr. Reuben continues to provide primary care for frail older persons, including attending on the inpatient geriatrics unit and making house calls. In his spare time, Dr. Reuben has written 8 plays and lyrics for more than 20 songs with composer Sidney Sharp. A compilation of the first 10 has been recorded.

Job Titles:

• Chief Technology Officer
• Founder

Dr. John Q. Walker is the Chief Technology Officer (CTO) and a founder of uMETHOD Health. His specialty, as a systems engineer, is collaborating with experts in other fields to build implementations of their highly complex visions. His work with leading researchers is bringing precision-medicine techniques to the breadth of chronic diseases. He was granted two recent patents for creating systems solutions for dementia and Alzheimer's disease. Dr. Walker led pioneering efforts in high-speed networking, wireless LANs ("Wi-Fi"), and voice-over-IP (VoIP) with advanced research-and-development teams at IBM. His doctorate in computer science is from UNC-Chapel Hill.

Dr. Ronald C. Petersen received a PhD in Experimental Psychology from the University of Minnesota and graduated from Mayo Medical School in Rochester, Minn., in 1980. He completed an internship in Medicine at Stanford University Medical Center and returned to the Mayo Clinic to complete a residency in Neurology. That was followed by a fellowship in Behavioral Neurology at Harvard University Medical School/Beth Israel Hospital in Boston, Mass. Dr. Petersen joined the staff of the Mayo Clinic in 1986 and became a Professor of Neurology in 1996. He was named the Cora Kanow Professor of Alzheimer's Disease Research in 2000 and Mayo Clinic Distinguished Investigator in 2011. He is currently the Director of the Mayo Alzheimer's Disease Research Center and the Mayo Clinic Study of Aging and has authored over 1,000 peer-reviewed articles on memory disorders, aging, and Alzheimer's disease. Dr. Petersen is one of the recipients of the 2004 MetLife Award for Medical Research in Alzheimer's Disease and the 2005 Potamkin Prize for Research in Picks, Alzheimer's and Related Disorders of the American Academy of Neurology. He received the Khachaturian Award in 2012 and the Henry Wisniewski Lifetime Achievement Award in 2013 from the Alzheimer's Association. In 2011 he was appointed by the Secretary of Health and Human Services to serve as the Chair of the Advisory Committee on Research, Care and Services for the National Alzheimer's Disease Plan, and in 2014, he was appointed to the World Dementia Council by the UK government. In 2021, he was given the Lifetime Achievement Award for Alzheimer's Disease Therapeutic Research.

Job Titles:

• Chairman of the Cure Alzheimer 's Fund Research Leadership Group
• Vice - Chair of Neurology

Dr. Rudolph E. Tanzi is the Vice-Chair of Neurology (Research), Director of the Genetics and Aging Research Unit, Co-Director of the Henry and Allison McCance Center for Brain Health, and Co-Director of the Mass General Institute for Neurodegenerative Disease at Massachusetts General Hospital. He also serves as the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School. Dr. Tanzi serves as Chair of the Cure Alzheimer's Fund Research Leadership Group and on numerous scientific advisory and editorial boards, He has published over 650 research papers (>150,000 citations) and is one of the top 50 most cited neuroscientists in the world. He has received the highest awards in his field, including the Metropolitan Life Foundation Award, Potamkin Prize, Ronald Reagan Award, Oneness in Humanity Award, Silver Innovator Award, the Smithsonian American Ingenuity Award, the Brain Research Foundation Award, and the Kary Mullis Award for Medical Research. He has also been named to TIME magazine's list of TIME100 Most Influential People in the World. Dr. Tanzi is also a New York Times-bestselling author, who has co-authored the books Decoding Darkness, and bestsellers, Super Brain, Super Genes, and The Healing Self, for which he has hosted several television shows on PBS. In his spare time, he plays studio keyboards for Aerosmith and other musicians.

Dr. Suzanne E. Schindler is a clinical neurologist and neuroscientist focused on improving the diagnosis and treatment of Alzheimer disease. She completed the MD/PhD program at Washington University, where she studied the basic biology of apolipoprotein E metabolism in the laboratory of Dr. David Holtzman. Dr. Schindler then trained in clinical neurology at Washington University and completed a fellowship in dementia under Drs. John Morris, Anne Fagan, and Marc Diamond. Currently, Dr. Schindler sees patients with memory concerns, coordinates biomarker testing for the Washington University Memory Diagnostic Center, and attends on the inpatient neurology consult service. She leads the Fluid Biomarker Core for the Knight Alzheimer Disease Research Center and a project for the Adult Children Study. She received a large R01 to evaluate the relationships between plasma biomarkers, other biomarker measures, and symptomatic Alzheimer disease. She works closely with Dr. Randall Bateman on validation of novel fluid biomarkers. She is very interested in translating research findings into clinical practice. Further, she has a particular focus on understanding and reducing disparities in healthcare. Dr. Schindler has served on a Scientific Advisory Board for Eisai.

Job Titles:

• Director of the National Institute of Neurological Disorders
• Director, National Institute of Neurological Disorders and Stroke

Dr. Walter J. Koroshetz serves as Director of the National Institute of Neurological Disorders and Stroke (NINDS), which overseas much of the Alzheimer Related Dementia research at the National Institutes of Health (NIH). He joined NINDS in 2007 as Deputy Director and has held leadership roles in a number of NIH and NINDS programs including co-leading the NIH's BRAIN Initiative, the NIH RECOVER Initiative in the study of Post Acute Sequelae of COVID-19, NIH Blueprint for Neuroscience, the NIH Post Acute Sequelae of Covid-19 Initiative, the Traumatic Brain Injury Center collaboration between the NIH intramural and the Uniformed Health Services University, the Helping to End Addiction Long Term (HEAL) Initiative. He co-leads a number of NIH Common Fund's programs including the Undiagnosed Disease Network, the Acute to Chronic Pain Transition programs, Somatic Gene Editing program, and Somatic Cell Transformational ALS research program, and he was instrumental in founding the NIH Office of Emergency Care Research. Before joining NINDS, Dr. Koroshetz served as Vice Chair of the neurology service and Director of stroke and neurointensive care services at Massachusetts General Hospital (MGH). He was a professor of Neurology at Harvard Medical School (HMS) and led neurology resident training at MGH between 1990 and 2007. Over that same period, he co-directed the HMS Neurobiology of Disease Course with Drs. Edward Kravitz and Robert H Brown. A native of Brooklyn, N.Y., Dr. Koroshetz graduated from Georgetown University and received his medical degree from the University of Chicago. He trained in internal medicine at the University of Chicago and Massachusetts General Hospital. He then trained in Neurology and Neuroscience at MGH and Harvard Neurobiology focusing on how synaptic mechanisms might contribute to neuronal death including in Alzheimer's disease. His early research in the lab and clinic focused on Huntington's disease and with the team at MGH performed the first study of pre-symptomatic testing based on linkage analysis. A major focus of his clinical research career was the development of measures in patients that reflect the underlying biology of their conditions. This led to brain the development and validation of imaging techniques including Magnetic Resonance (MR) spectroscopy in Huntington's disease; diffusion/perfusion MR and CT X-ray angiography and perfusion imaging in stroke. These stroke imaging tools are now commonplace in stroke care. Guided by these tools he pioneered acute clot removal for acute stroke patients with large artery occlusion, which is now practiced at Comprehensive stroke centers around the country. Through his work with the American Academy of Neurology, American Stroke Association and ACGME, he played a significant role in the revolution in acute stroke care in the U.S. and the growth of the neurointensive care field.

Job Titles:

• Executive Director, Global CEO Initiative on Alzheimer 's Disease

Drew Holzapfel is the Executive Director of the Global CEO Initiative on Alzheimer's Disease, a coalition of leading corporations investing in Alzheimer's disease research, treatment, and care. He is also a Partner at High Lantern Group, a healthcare consultancy focused on the intersection of business strategy and public policy. Mr. Holzapfel brings nearly two decades of healthcare experience in government and corporate affairs, sales, and marketing in global biotechnology, pharmaceutical, and U.S. government organizations to a diverse client base. He has spent over 10 years working on Alzheimer's disease in a range of positions. Prior to joining High Lantern Group, Mr. Holzapfel was at Pfizer, where he most recently led efforts around the company's Alzheimer's program and advanced Alzheimer's and aging issues through development of commercial strategy and advocacy with international organizations, nongovernmental organizations, nonprofits, and other key stakeholders.

Job Titles:

• Certified Clinical Neuropsychologist and Associate Professor

Dustin B. Hammers is a board-certified clinical neuropsychologist and Associate Professor in the Department of Neurology at Indiana University (IU). Joining the department in 2021, he was previously faculty at the University of Utah starting in 2011. Dr. Hammers is the primary neuropsychologist involved in the NIA-funded Longitudinal Early-Onset Alzheimer's Disease Study (LEADS), and he is currently the Principal Investigator on the NIA- and Alzheimer's Association-funded study Lifestyle Interventions for the Treatment of Early-Onset AD Study (LITES). His research has emphasized the evaluation of diagnostic consistency between cognitive and advanced AD biomarkers (β-amyloid and tau) in an effort to improve diagnostic accuracy. Additional areas of interest have included examining the assessment of cognitive change over time, teleneuropsychology, and the detection of early memory decline in elderly and dementia populations through computerized batteries and novel learning measures. He currently serves as Associate Editor of Developmental Neuropsychology and Grand Rounds Editor of The Clinical Neuropsychologist, and has been the Guest Editor for a special issue from the Journal of Clinical and Experimental Neuropsychology. In addition to being the lead neuropsychologist for the multi-center NIA-funded Anti-NMDA Receptor Encephalitis ExTINGUISH trial, he is the past Chair of the Committee on Rural Health of the American Psychological Association (APA), and is currently a Liaison for the Public Interest Advisory Committee, APA Society for Clinical Neuropsychology.

Job Titles:

• Professor and Director

George T. Grossberg is Professor and Director, Geriatric Psychiatry, at Saint Louis University School of Medicine (Mo.). He completed his medical degree at the St. Louis University School of Medicine. His postdoctoral training included an internship at St. John's Mercy Medical Center and a residency in the St. Louis University Department of Psychiatry. A Diplomat of the National Board of Medical Examiners and a Distinguished Fellow of the American Psychiatric Association, Dr. Grossberg holds membership in several professional societies. Additionally, he started the first Geriatric Psychiatry program in Missouri and the first Alzheimer's Disease Community Brain Bank. He is a former president of the American Association for Geriatric Psychiatry and Past President of the International Psychogeriatric Association (IPA). He is a consultant in the development of protocols for central nervous system disorders in older patients. He is involved in a variety of basic as well as clinical research projects in the area of dementing disorders, with a focus on behavioral disturbances in Alzheimer's disease. Dr. Grossberg has been a leader in developing mental health programs and in treatment and research in geriatrics.

Job Titles:

• Chairman and Co - Founder, UsAgainstAlzheimer's

Job Titles:

• Foundation Endowed Professor, Global Brain Health Institute Professor, Memory and Aging Center, University of California, San Francisco

Kate Possin is a Professor at the UCSF Memory and Aging Center in the Department of Neurology and at the Global Brain Health Institute, where she holds the John Douglas French Foundation Endowed Professorship. Dr. Possin's research program is focused on improving the detection, diagnosis, and care for people with neur...

Job Titles:

• Professor

Jeffrey Cummings, MD, ScD(HC), is the Joy Chambers-Grundy Professor of Brain Science, Director of the Chambers-Gundy Center for Transformative Neuroscience, and Co-Director of the Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV). Dr. Cummings is globally known for his contributions to Alzheimer's research, drug development, and clinical trials. He has been recognized for his research and leadership contributions in the field of Alzheimer's disease through many awards including the Ronald and Nancy Reagan Research Award of the national Alzheimer's Association (2008), Lifetime Achievement Award of the Society for Behavioral and Cognitive Neurology (2017), Distinguished Scientist Award of the American Association of Geriatric Psychiatry (2010), Bengt Winblad Lifetime Achievement Award from the national Alzheimer's Association (2019), and the Alzheimer's Drug Discovery Foundation's Melvin R. Goodes Prize. He was featured in Gentleman's Quarterly (June 2009) as a "Rock Star of Science™." Dr. Cummings completed Neurology residency and a Fellowship in Behavioral Neurology at Boston University, followed by a Research Fellowship in Neuropathology and Neuropsychiatry at the National Hospital for Nervous Diseases, Queen Square, London. Dr. Cummings was formerly Director of the Mary S. Easton Center for Alzheimer's Disease Research at UCLA, and Director of the Cleveland Clinic Lou Ruvo Center for Brain Health. Dr. Cummings's interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society. He has authored or edited 43 books and published over 800 peer-reviewed papers. Joy Chambers-Grundy Professor of Brain Science, Co-Director of Pam Quirk Brain Health and Biomarker Laboratory, Director of Chambers-Grundy Center for Transformative Neuroscience, University of Nevada, Las Vegas

Job Titles:

• Senior Vice President

As Senior Vice President, Dr. Wood also helps direct organization-wide strategy and policy-development activities in addition to actively participating in the work of the AAFP Board of Directors. She is based at the AAFP's headquarters office in Leawood, Kans.

Job Titles:

• Professor at the UCSF Memory

Kate Possin is a Professor at the UCSF Memory and Aging Center in the Department of Neurology and at the Global Brain Health Institute, where she holds the John Douglas French Foundation Endowed Professorship. Dr. Possin's research program is focused on improving the detection, diagnosis, and care for people with neurodegenerative disease. She has designed and developed cognitive measures for early diagnosis and disease monitoring, including tablet-based measures ("TabCAT") that are easy to use in everyday clinical and research settings. In addition, Dr. Possin directs the Care Ecosystem, a telephone-based collaborative care model for people with dementia and their caregivers that improves patient quality of life and caregiver well-being, while reducing emergency-related health care costs.

Job Titles:

• Principal With Faegre Drinker Consulting
• Senior Strategic Counsel, UsAgainstAlzheimer's

Ms. Debra Lappin serves as a principal with Faegre Drinker Consulting. She is recognized across government, academic, and nonprofit sectors as a leading strategist in public health and science policy. Ms. Lappin consults on innovative precompetitive partnerships, global consortia, and other strategic alliances among academic research institutions, voluntary health agencies, government, and industry. She brings special expertise in regulatory science where her practice leads a range of initiatives for patient-focused drug development and the generation of value models for payment and coverage determinations. A skilled facilitator of scientific meetings, Ms. Lappin brings an ability to translate and synthesize complex scientific information for diverse audiences and to elicit collective and balanced input. She is respected and trusted by senior leaders across the nation's health agencies, having served on advisory boards to the directors of both the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC), and as Chair of the National Arthritis Foundation, President of the Council for American Medical Innovation, and a member of the Boards of Research!America, the Next Fifty Initiative, and the Ludeman Center for Women's Health Research. Over eight years, she has supported UsA2 in the design of a number of its defining initiatives, including the Global CEO Initiative on Alzheimer's, the Global Alzheimer's Platform, the Alzheimer's Disease Patient and Caregiver Engagement initiatives and, most recently, the Alzheimer's Disease Evidence Accelerator, a platform for the collection, linkage, and sharing of real world data in Alzheimer's. Ms. Lappin has no conflicts of interest to disclose.

Job Titles:

• Chief Operating Officer, UsAgainstAlzheimer's

Shelley Moore Capito was elected by the people of West Virginia to the United States Senate in 2014, and re-elected in 2020. Ms. Capito became the first female Senator in West Virginia's history and in 2020 was reelected with the largest margin of victory for a Republican in state history-winning more than 70 percent of the vote and all 55 counties, surpassing the previous mark she set in 2014, when she won more than 62 percent of the vote and all 55 counties. After serving West Virginia's Second Congressional District in the U.S. House of Representatives for 14 years, and as a member of the West Virginia House of Delegates for four years prior, Senator Capito decided to run for Senate to be an even stronger voice for the Mountain State. She also saw an opportunity to restore order to a Senate stuck in gridlock for far too long. She believes that today's challenges demand bipartisan solutions and cooperation across the aisle to advance legislation that benefits West Virginia and the country as a whole. Senator Capito is committed to being accessible and responsive to her fellow West Virginians and regularly travels, with proper health and safety precautions in place, to hear from and meet with West Virginians. For the 118th Congress Senator Capito serves on the Appropriations Committee; the Commerce, Science, and Transportation Committee; the Environment and Public Works (EPW) Committee as ranking member; and the Rules and Administration Committee. This committee portfolio puts her in a strong position to create new opportunities in the Mountain State and fight for West Virginia priorities, jobs, and families. Senator Capito also serves as the Vice Chairman of the Senate Republican Conference, the number five position in Senate Republican leadership. As a member of the Committee on Appropriations, Senator Capito works to ensure West Virginia's priorities are represented when our nation's funding decisions are made. During her time on the committee, she has served as chair of the Legislative Branch Subcommittee, the Financial Services and General Government Subcommittee, and the Homeland Security Subcommittee. Senator Capito currently serves as the top Republican on the Labor, Health, and Human Services, Education, and Related Agencies Appropriations Subcommittee, where she oversees funding across a large range of programs within the U.S. She has been a member of

Job Titles:

• Professor of Gerontology

Lisa L. Barnes, PhD, is the Alla V. and Solomon Jesmer Professor of Gerontology and Geriatric Medicine and a cognitive neuropsychologist within the Rush Alzheimer's Disease Center at Rush University Medical Center. She is also the Associate Director of the Rush Alzheimer's Disease Research Center. She received her PhD from the University of Michigan in biopsychology and completed a postdoctoral fellowship in cognitive neuroscience at the University of California, Davis. She has been a faculty member at Rush Medical College since 1999. Dr. Barnes has received many NIH grants and has published over 300 manuscripts. Her research interests include disparities in chronic diseases of aging, cognitive decline, and risk factors for Alzheimer's disease. She is the Principal Investigator of the Minority Aging Research Study (MARS), which has been funded by NIA since 2004, and the Clinical Core Leader for the Rush African American Clinical Core. She advocates for recruitment of under-represented groups into clinical studies and has received many awards and fellowships.

Job Titles:

• Vice President and Senior Advisor of Health Equity and Access at UsAgainstAlzheimer's
• Vice President and Senior Advisor, Health Equity, UsAgainstAlzheimer's

Stephanie J. Monroe is Vice President and Senior Advisor of Health Equity and Access at UsAgainstAlzheimer's, a national advocacy organization based in Washington, D.C. She leads the Center for Brain Health Equity, which is supported in part by CDC BOLD funding. She also directs African Americans Against Alzheimer's, founded in 2013 and the first national network created specifically to respond to Alzheimer's disease's disparate impact on African Americans. By working nationally, locally, and through strategic partnerships, African Americans Against Alzheimer's is raising awareness of the impact of Alzheimer's health disparities on communities of color and women, the need for greater minority participation in clinical trials to find better treatments and hopefully a cure, and the importance of all communities, especially those most at risk, to begin to focus on brain health and adopt risk reduction strategies that promote brain health and healthy aging. An attorney with three decades of federal public policy experience. Ms. Monroe is former Assistant Secretary of Education for Civil Rights. Prior to serving in that position, she ended a 25-year career on Capitol Hill after holding a number of key staff positions in the United States Congress, including Chief Counsel of the U.S. Senate Committee on Health, Education, Labor, and Pensions, and Staff Director of the Senate Subcommittee on Children and Families. In addition to her work in Alzheimer's, Ms. Monroe serves on the National Academy of Sciences Board for Children, Youth, and Families, addressing issues that impact vulnerable families, including health and education. She also advises academic centers, industry partners, federal agencies, and others on strategies to achieve inclusive participation clinical trials.

Job Titles:

• Vice President, U.S. Alzheimer 's Disease Commercial, Eisai Inc

Thomas D. Fagan, Jr., serves as Vice President, U.S. Alzheimer's Disease Commercial, for Eisai Inc. In this role, he is responsible for leading the commercial strategy for the company's Alzheimer's disease (AD) business in the U.S. He also serves as a member of the company's Executive Committee for the Americas. Mr. Fagan has an extensive leadership background and strong record in driving business results. His experience includes product and brand development, commercialization, business development and alliance management across pharmaceutical, device and diagnostic businesses. Since joining Eisai in July 2022, he has led the development and implementation of the commercial launch and growth strategy for the company's U.S. Alzheimer's disease (AD) business, following the accelerated approval of a compound by the FDA in January 2023 and then its traditional approval in July 2023. Prior to Eisai, Mr. Fagan served as Chief Operating Officer at VMS Biomarketing, Inc., a specialty clinical educator firm, where he directly oversaw field nurse educator teams, as well as digital engagement and IT platform, data and analytics, process operations and compliance. Prior to this position, he spent a significant portion of his career at Eli Lilly & Company, where he began in corporate finance then held progressive roles in sales, marketing, and related commercial functions, including seven years in roles dedicated to AD. As Global Commercial Leader, Alzheimer's Disease, he designed, built and led commercial teams to launch a first-in-class PET radiopharmaceutical used in the diagnosis of AD. He also served as Eli Lilly's Global Brand Development Leader for AD, in which he was the commercial lead on an alliance for an FDA-approved product for the treatment of early AD. Mr. Fagan earned his Master of Business Administration (MBA) in general management from Stanford University. He holds a Bachelor of Arts degree in Economics from DePauw University, where he graduated summa cum laude and is a member of Phi Beta Kappa.

Job Titles:

• CEO
• Founder
• Founder and CEO, Icometrix

Wim Van Hecke, PhD, is the founder and CEO of icometrix, a leading technology company that is focused on improving the lives of people with neurological conditions. The FDA-cleared and CE-marked icobrain AI solution quantifies clinically meaningful information from brain MRI and CT scans. Specifically for Alzheimer's disease and dementia, icobrain evaluates volumes of the hippocampus, different brain lobes, and so on in individuals and compares these with a large healthy population. A specific solution for ARIA monitoring has been developed in collaboration with the pharmaceutical industry and is FDA-pending. Dr. Van Hecke is an academic engineer by training with two master's degrees in applied biomedical engineering and neuroimaging, and a PhD in medicine. He is the author of more than 250 scientific publications and the editor of a clinical neuroimaging handbook. He is also a visiting professor at the University of Brussels.